Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia | Zendy

Mrinal M. Patnaik | Zendy; David A. Sallman | Zendy; Abhishek A. Mangaonkar | Zendy; Rachel Heuer | Zendy; Jeffery Hirvela | Zendy; Darci Zblewski | Zendy; Aref AlKali | Zendy; Moritz Binder | Zendy; Maria E. Balasis | Zendy; Hannah Newman | Zendy; Christopher T. Letson | Zendy; Traci Kruer | Zendy; Naseema Gangat | Zendy; Rami S. Komrokji | Zendy; Ayalew Tefferi | Zendy; Adrian Lo | Zendy; Ted Shih | Zendy; Cameron Durrant | Zendy; Alan F. List | Zendy; Eric Padron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

Author(s) -

Mrinal M. Patnaik,

David A. Sallman,

Abhishek A. Mangaonkar,

Rachel Heuer,

Jeffery Hirvela,

Darci Zblewski,

Aref AlKali,

Moritz Binder,

Maria E. Balasis,

Hannah Newman,

Christopher T. Letson,

Traci Kruer,

Naseema Gangat,

Rami S. Komrokji,

Ayalew Tefferi,

Adrian Lo,

Ted Shih,

Cameron Durrant,

Alan F. List,

Eric Padron

Publication year - 2020

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019004352

Subject(s) - chronic myelomonocytic leukemia , granulocyte macrophage colony stimulating factor , medicine , immunology , recombinant dna , antibody , neuroblastoma ras viral oncogene homolog , leukemia , cancer research , biology , cancer , cytokine , gene , bone marrow , myelodysplastic syndromes , genetics , colorectal cancer , kras

In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) was associated with clinically meaningful responses in 5 of 15 patients with relapsed or refractory chronic myelomonocytic leukemia (CMML). Preliminary data suggest that this approach may be tractable in CMML bearing activating NRAS mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research